TY - JOUR
T1 - Exploring Overlaps Between the Genomic and Environmental Determinants of LVH and Stroke
T2 - A Multicenter Study in West Africa
AU - SIREN Team as part of H3Africa Consortium.
AU - Adeoye, Abiodun M.
AU - Ovbiagele, Bruce
AU - Kolo, Philip
AU - Appiah, Lambert
AU - Aje, Akinyemi
AU - Adebayo, Oladimeji
AU - Sarfo, Fred
AU - Akinyemi, Joshua
AU - Adekunle, Gregory
AU - Agyekum, Francis
AU - Shidali, Vincent
AU - Ogah, Okechukwu
AU - Lackland, Dan
AU - Gebregziabher, Mulugeta
AU - Arnett, Donna
AU - Tiwari, Hemant K.
AU - Akinyemi, Rufus
AU - Olagoke, Ojo Olakanmi
AU - Oguntade, Ayodipupo Sikiru
AU - Olunuga, Taiwo
AU - Uwanruochi, Kelechi
AU - Jenkins, Carolyn
AU - Adadey, Patrick
AU - Iheonye, Henry
AU - Owolabi, Lukman
AU - Obiako, Reginald
AU - Akinjopo, Samuel
AU - Armstrong, Kevin
AU - Akpalu, Albert
AU - Fakunle, Adekunle
AU - Saulson, Raelle
AU - Aridegbe, Mayowa
AU - Olowoyo, Paul
AU - Osaigbovo, Godwin
AU - Akpalu, Josephine
AU - Fawale, Bimbo
AU - Adebayo, Philip
AU - Arulogun, Oyedunni
AU - Ibinaiye, Philip
AU - Agunloye, Atinuke
AU - Ishaq, Naser
AU - Wahab, Kolawole
AU - Akpa, Onoja
AU - Adeleye, Omisore
AU - Bock-Oruma, Andrew
AU - Ogbole, Godwin
AU - Melikam, Sylvia
AU - Yaria, Joseph
AU - Ogunjimi, Luqman
AU - Salaam, Abdul
N1 - Publisher Copyright:
© 2017 World Heart Federation (Geneva)
PY - 2017/6
Y1 - 2017/6
N2 - Background Whether left ventricular hypertrophy (LVH) is determined by similar genomic and environmental risk factors with stroke, or is simply an intermediate stroke marker, is unknown. Objectives We present a research plan and preliminary findings to explore the overlap in the genomic and environmental determinants of LVH and stroke among Africans participating in the SIREN (Stroke Investigative Research and Education Network) study. Methods SIREN is a transnational, multicenter study involving acute stroke patients and age-, ethnicity-, and sex-matched control subjects recruited from 9 sites in Ghana and Nigeria. Genomic and environmental risk factors and other relevant phenotypes for stroke and LVH are being collected and compared using standard techniques. Results This preliminary analysis included only 725 stroke patients (mean age 59.1 ± 13.2 years; 54.3% male). Fifty-five percent of the stroke subjects had LVH with greater proportion among women (51.6% vs. 48.4%; p < 0.001). Those with LVH were younger (57.9 ± 12.8 vs. 60.6 ± 13.4; p = 0.006) and had higher mean systolic and diastolic blood pressure (167.1/99.5 mm Hg vs 151.7/90.6 mm Hg; p < 0.001). Uncontrolled blood pressure at presentation was prevalent in subjects with LVH (76.2% vs. 57.7%; p < 0.001). Significant independent predictors of LVH were age <45 years (adjusted odds ratio [AOR]: 1.91; 95% confidence interval [CI]: 1.14 to 3.19), female sex (AOR: 2.01; 95% CI: 1.44 to 2.81), and diastolic blood pressure > 90 mm Hg (AOR: 2.10; 95% CI: 1.39 to 3.19; p < 0.001). Conclusions The prevalence of LVH was high among stroke patients especially the younger ones, suggesting a genetic component to LVH. Hypertension was a major modifiable risk factor for stroke as well as LVH. It is envisaged that the SIREN project will elucidate polygenic overlap (if present) between LVH and stroke among Africans, thereby defining the role of LVH as a putative intermediate cardiovascular phenotype and therapeutic target to inform interventions to reduce stroke risk in populations of African ancestry.
AB - Background Whether left ventricular hypertrophy (LVH) is determined by similar genomic and environmental risk factors with stroke, or is simply an intermediate stroke marker, is unknown. Objectives We present a research plan and preliminary findings to explore the overlap in the genomic and environmental determinants of LVH and stroke among Africans participating in the SIREN (Stroke Investigative Research and Education Network) study. Methods SIREN is a transnational, multicenter study involving acute stroke patients and age-, ethnicity-, and sex-matched control subjects recruited from 9 sites in Ghana and Nigeria. Genomic and environmental risk factors and other relevant phenotypes for stroke and LVH are being collected and compared using standard techniques. Results This preliminary analysis included only 725 stroke patients (mean age 59.1 ± 13.2 years; 54.3% male). Fifty-five percent of the stroke subjects had LVH with greater proportion among women (51.6% vs. 48.4%; p < 0.001). Those with LVH were younger (57.9 ± 12.8 vs. 60.6 ± 13.4; p = 0.006) and had higher mean systolic and diastolic blood pressure (167.1/99.5 mm Hg vs 151.7/90.6 mm Hg; p < 0.001). Uncontrolled blood pressure at presentation was prevalent in subjects with LVH (76.2% vs. 57.7%; p < 0.001). Significant independent predictors of LVH were age <45 years (adjusted odds ratio [AOR]: 1.91; 95% confidence interval [CI]: 1.14 to 3.19), female sex (AOR: 2.01; 95% CI: 1.44 to 2.81), and diastolic blood pressure > 90 mm Hg (AOR: 2.10; 95% CI: 1.39 to 3.19; p < 0.001). Conclusions The prevalence of LVH was high among stroke patients especially the younger ones, suggesting a genetic component to LVH. Hypertension was a major modifiable risk factor for stroke as well as LVH. It is envisaged that the SIREN project will elucidate polygenic overlap (if present) between LVH and stroke among Africans, thereby defining the role of LVH as a putative intermediate cardiovascular phenotype and therapeutic target to inform interventions to reduce stroke risk in populations of African ancestry.
UR - https://www.scopus.com/pages/publications/85019726755
U2 - 10.1016/j.gheart.2017.01.001
DO - 10.1016/j.gheart.2017.01.001
M3 - Article
C2 - 28302552
AN - SCOPUS:85019726755
SN - 2211-8160
VL - 12
SP - 107-113.e5
JO - Global Heart
JF - Global Heart
IS - 2
ER -